Although there are no RCTs examining the effect of SGLT-2 inhibitors for patients with HFpEF and AF, subgroup analyses of the EMPEROR-Preserved [19] and the EMPERIAL-Preserved [22] showed that SGLT2-inhibitos improved a composite of hospitalization for HF and CV death and exercise capacity similarly for HFpEF patients with AF and those without AF. The gene discussed is SLC5A2; the disease is hydrops fetalis.